A metabolic biomarker predicts Parkinson’s disease at the early stages in patients and animal models
David Mallet, … , Florence Fauvelle, Sabrina Boulet
David Mallet, … , Florence Fauvelle, Sabrina Boulet
Published December 16, 2021
Citation Information: J Clin Invest. 2022;132(4):e146400. https://doi.org/10.1172/JCI146400.
View: Text | PDF
Clinical Research and Public Health Metabolism Neuroscience

A metabolic biomarker predicts Parkinson’s disease at the early stages in patients and animal models

Abstract

Background Care management of Parkinson’s disease (PD) patients currently remains symptomatic, mainly because diagnosis relying on the expression of the cardinal motor symptoms is made too late. Earlier detection of PD therefore represents a key step for developing therapies able to delay or slow down its progression.Methods We investigated metabolic markers in 3 different animal models of PD, mimicking different phases of the disease assessed by behavioral and histological evaluation, and in 3 cohorts of de novo PD patients and matched controls (n = 129). Serum and brain tissue samples were analyzed by nuclear magnetic resonance spectroscopy and data submitted to advanced multivariate statistics.Results Our translational strategy reveals common metabolic dysregulations in serum of the different animal models and PD patients. Some of them were mirrored in the tissue samples, possibly reflecting pathophysiological mechanisms associated with PD development. Interestingly, some metabolic dysregulations appeared before motor symptom emergence and could represent early biomarkers of PD. Finally, we built a composite biomarker with a combination of 6 metabolites. This biomarker discriminated animals mimicking PD from controls, even from the first, nonmotor signs and, very interestingly, also discriminated PD patients from healthy subjects.Conclusion From our translational study, which included 3 animal models and 3 de novo PD patient cohorts, we propose a promising biomarker exhibiting a high accuracy for de novo PD diagnosis that may possibly predict early PD development, before motor symptoms appear.Funding French National Research Agency (ANR), DOPALCOMP, Institut National de la Santé et de la Recherche Médicale, Université Grenoble Alpes, Association France Parkinson.

Authors

David Mallet, Thibault Dufourd, Mélina Decourt, Carole Carcenac, Paola Bossù, Laure Verlin, Pierre-Olivier Fernagut, Marianne Benoit-Marand, Gianfranco Spalletta, Emmanuel L. Barbier, Sebastien Carnicella, Véronique Sgambato, Florence Fauvelle, Sabrina Boulet

×

Figure 4

Brain metabolic profile of 6-OHDA rats is gradually modified during PD progression, consistently with serum results.

Options: View larger image (or click on image) Download as PowerPoint
Brain metabolic profile of 6-OHDA rats is gradually modified during PD p...
(A) Example of 1H HRMAS NMR spectra of 6-OHDA rat rain (DS) at 500 MHz. Assignment was as follows: 1, lactate; 2, alanine; 3, GABA; 4, Acetate; 5, N, acetylaspartate; 6, glutamate; 7, glutamine; 8, aspartate; 9, gluthation; 10, phosphocreatine and creatine; 11, choline; 12, phosphoethanolamine; 13, PC; 14, glycerophosphocholine; 15, myoinositol; 16, taurine; 17, scyllo-inositol; 18, glycine; 19, ascorbate. (B) Score plot of the OPLS model built with 1H HRMAS NMR spectra of DS versus the first predictive and the first orthogonal components (6-OHDA DS OPLS model). There is clear color gradation from left to right, showing that metabolic profiles evolve with PD progression. R2Y = 0.883; Q2 = 0.703, 1 predictive and 3 orthogonal components, CV ANOVA P = 0.0003. (C) Relative amplitude of metabolites in DS in sham-operated (n = 15), prodromal-like (n = 10), and clinical-like (n = 9) 6-OHDA animals for the 5 key metabolites implicated in metabolic gradation observed in the OPLS, i.e., alanine, glutamate, lactate, phosphocreatine, creatine (PCR), and taurine. (D) Score plot of the OPLS models built with 1H HRMAS NMR spectra, of Nacc versus the first predictive and first orthogonal components (6-OHDA Nacc OPLS model). Color gradation from left to right shows the evolution of metabolic profiles with PD progression. R2Y = 0.690; Q2 = 0.523, 1 predictive and 1 orthogonal component, CV ANOVA, P = 0.0005. (E) Relative amplitude of metabolites in Nacc in sham-operated (n = 14), prodromal-like (n = 10), and clinical-like (n = 7) 6-OHDA animals for the 4 key metabolites implicated in metabolic gradation observed in the OPLS, i.e., alanine, choline, lactate, and PC. Data are represented as mean ± SEM, 1-way ANOVA followed by Tukey’s post hoc test and correction for multiple comparisons. *P ≤ 0.05.